Keyphrases
AI Platform
25%
Anti-PD-1
25%
Anti-PD-1 Therapy
100%
Antigen-specific T Cell Response
25%
Antitumor Efficacy
25%
Cancer Peptide Vaccine
25%
CD4+
50%
CD4+ T Cells
25%
CD8+ T Cells
50%
Clinical Response
25%
Dose Escalation
50%
Dose Level
100%
Dose-escalation Study
100%
ELISpot Assay
25%
High Dose
25%
Immune Response
25%
Immunization
25%
Immunogenic
25%
Immunogenicity
25%
Immunological Response
25%
Interim Data
25%
Intramuscular Injection
25%
Liposomal
25%
Local Guidelines
25%
Metastatic Melanoma
100%
Neoantigen
75%
Neoantigen Vaccine
100%
Neopeptide
25%
Next-generation Vaccines
25%
Objective Response Rate
25%
Objective Tumor Response
25%
Partial Response
50%
Pembrolizumab
25%
Peptide-based
100%
Personalized Therapy
25%
Safety Efficacy
25%
Serious Adverse Events
25%
Survival Response
25%
T-cell Immunogenicity
25%
T-cell Mediated
25%
Third Dose
25%
Tolerability
25%
Tumor
25%
Tumor Immunity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Base
33%
CD8 Antigen
66%
Clinical Study
33%
Immunogenicity
66%
Intramuscular Injection
33%
Malignant Neoplasm
33%
Metastatic Melanoma
100%
Neoplasm
66%
Pembrolizumab
33%
Peptide Vaccine
33%
Tolerability
33%
Immunology and Microbiology
Artificial Intelligence
14%
CD4
14%
Cytotoxic T-Cell
28%
Drug Megadose
14%
Immune Response
14%
Immunogenicity
28%
Neoantigen
100%
Pembrolizumab
14%
Peptide Vaccine
14%
T Cell
42%
T-Helper Cell
28%
Vaccine Efficacy
100%